New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.

Dr. Daniel Drucker shares the US$3 million prize with four colleagues in the U.S. and Denmark for discovering the GLP-1 hormone that's used in medications like Ozempic.

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

The program offered eligible patients the option to travel for radiation therapy treatment at two clinics in Bellingham, Wash ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

Novo Nordisk ) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to ...

THE Simpsons fans have been left stunned as the show’s iconic twins Patty and Selma Bouvier have undergone a shock ‘Ozempic ...

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines ...

Vancouver's city manager has apologized for voting delays in Saturday's byelection after residents faced hours-long waits to ...

Bathing your newborn in the kitchen sink might look adorable—and yes, it’s a favorite for social media snaps—but experts say ...

DAILYMAIL.COM LIVE BLOG: Trump is not backing down on his tariffs declaring there's 'no inflation' days after sending the ...